Drugs Made in America Acquisition Corp. Announces Advisory Team
Drugs Made in America Acquisition Corp. (DMAAU) has announced the formation of an advisory team to lead its acquisition efforts. The team's mission is to acquire a revenue-generating business focused on end-to-end production, manufacturing, and distribution of drugs in America.
Under CEO Lynn Stockwell's direction, the advisory team includes notable members: Charles C. Conaway, chairman of The Sabre group and former President of CVS ; Paul J. Mastronardi, a third-generation greenhouse grower recognized as a Top 40 Under 40 honoree; and Edward A. Robinson, former CEO of BMW Financial Services N.A.
The initiative aims to establish domestic drug production, create jobs, mitigate national security risks, and ensure Americans have access to clean, pure, cost-efficient medications through a U.S.-based supply chain. The team will leverage their networks to pursue proprietary transaction opportunities.
Drugs Made in America Acquisition Corp. (DMAAU) ha annunciato la formazione di un team consultivo per guidare i suoi sforzi di acquisizione. La missione del team è acquisire un'azienda generatrice di entrate focalizzata sulla produzione, fabbricazione e distribuzione di farmaci negli Stati Uniti.
Sotto la direzione del CEO Lynn Stockwell, il team consultivo include membri di spicco: Charles C. Conaway, presidente del gruppo Sabre e ex presidente di CVS; Paul J. Mastronardi, un coltivatore di serre di terza generazione riconosciuto come uno dei Top 40 Under 40; e Edward A. Robinson, ex CEO di BMW Financial Services N.A.
L'iniziativa mira a stabilire una produzione domestica di farmaci, creare posti di lavoro, mitigare i rischi per la sicurezza nazionale e garantire agli americani l'accesso a farmaci puliti, puri e a costi contenuti attraverso una catena di approvvigionamento basata negli Stati Uniti. Il team sfrutterà le proprie reti per perseguire opportunità di transazione proprietarie.
Drugs Made in America Acquisition Corp. (DMAAU) ha anunciado la formación de un equipo asesor para liderar sus esfuerzos de adquisición. La misión del equipo es adquirir un negocio generador de ingresos centrado en la producción, fabricación y distribución de medicamentos en América.
Bajo la dirección del CEO Lynn Stockwell, el equipo asesor incluye miembros destacados: Charles C. Conaway, presidente del grupo Sabre y ex presidente de CVS; Paul J. Mastronardi, un cultivador de invernaderos de tercera generación reconocido como uno de los Top 40 Under 40; y Edward A. Robinson, ex CEO de BMW Financial Services N.A.
La iniciativa tiene como objetivo establecer la producción de medicamentos a nivel nacional, crear empleos, mitigar riesgos de seguridad nacional y garantizar que los estadounidenses tengan acceso a medicamentos limpios, puros y rentables a través de una cadena de suministro basada en EE.UU. El equipo aprovechará sus redes para buscar oportunidades de transacciones propietarias.
Drugs Made in America Acquisition Corp. (DMAAU)는 인수 노력을 이끌기 위한 자문 팀의 구성을 발표했습니다. 이 팀의 임무는 미국에서 약물의 전 과정 생산, 제조 및 유통에 초점을 맞춘 수익 창출 비즈니스를 인수하는 것입니다.
CEO Lynn Stockwell의 지휘 하에 자문 팀에는 저명한 멤버들이 포함되어 있습니다: Charles C. Conaway, Sabre 그룹의 회장 및 전 CVS 사장; Paul J. Mastronardi, Top 40 Under 40 수상자로 인정받은 3세대 온실 재배자; 그리고 Edward A. Robinson, 전 BMW Financial Services N.A. CEO입니다.
이 이니셔티브는 국내 약물 생산을 확립하고, 일자리를 창출하며, 국가 안보 위험을 완화하고, 미국인들이 미국 기반 공급망을 통해 깨끗하고 순수하며 비용 효율적인 약물에 접근할 수 있도록 보장하는 것을 목표로 합니다. 팀은 독점 거래 기회를 추구하기 위해 그들의 네트워크를 활용할 것입니다.
Drugs Made in America Acquisition Corp. (DMAAU) a annoncé la formation d'une équipe consultative pour diriger ses efforts d'acquisition. La mission de l'équipe est d'acquérir une entreprise génératrice de revenus axée sur la production, la fabrication et la distribution de médicaments en Amérique.
Sous la direction du PDG Lynn Stockwell, l'équipe consultative comprend des membres notables : Charles C. Conaway, président du groupe Sabre et ancien président de CVS ; Paul J. Mastronardi, un cultivateur de serres de troisième génération reconnu comme l'un des Top 40 Under 40 ; et Edward A. Robinson, ancien PDG de BMW Financial Services N.A.
Cette initiative vise à établir une production nationale de médicaments, à créer des emplois, à atténuer les risques pour la sécurité nationale et à garantir aux Américains l'accès à des médicaments propres, purs et rentables grâce à une chaîne d'approvisionnement basée aux États-Unis. L'équipe utilisera ses réseaux pour rechercher des opportunités de transactions propriétaires.
Drugs Made in America Acquisition Corp. (DMAAU) hat die Bildung eines Beratungsteams angekündigt, das die Akquisitionsbemühungen leiten soll. Die Mission des Teams besteht darin, ein umsatzgenerierendes Unternehmen zu erwerben, das sich auf die vollständige Produktion, Herstellung und Verteilung von Medikamenten in Amerika konzentriert.
Unter der Leitung von CEO Lynn Stockwell umfasst das Beratungsteam namhafte Mitglieder: Charles C. Conaway, Vorsitzender der Sabre-Gruppe und ehemaliger Präsident von CVS; Paul J. Mastronardi, ein drittgenerationaler Gewächshausbauer, der als einer der Top 40 Under 40 ausgezeichnet wurde; und Edward A. Robinson, ehemaliger CEO von BMW Financial Services N.A.
Die Initiative zielt darauf ab, die inländische Medikamentenproduktion zu etablieren, Arbeitsplätze zu schaffen, nationale Sicherheitsrisiken zu mindern und sicherzustellen, dass Amerikaner Zugang zu sauberen, reinen und kosteneffizienten Medikamenten über eine in den USA ansässige Lieferkette haben. Das Team wird sein Netzwerk nutzen, um proprietäre Transaktionsmöglichkeiten zu verfolgen.
- Formation of experienced advisory team with proven track record in healthcare and business development
- Strategic focus on domestic drug production addressing national security and supply chain concerns
- Team includes former CVS President who helped transform CVS into major healthcare company
- No specific acquisition targets identified yet
- Timeline for potential acquisitions not specified
Fort Lauderdale, FL, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Drugs Made in America Acquisition Corp. (Nasdaq: DMAAU), (the “Company”) today announced the formation of an advisory team to lead its effort towards acquiring a well-managed, revenue generating business for the foundation and development of “End to End production, manufacturing and distribution, for the Drugs Made In America Platform”. Under the direction of Lynn Stockwell, Chief Executive Officer of DMAAU, the advisory team will proactively pursue the deliverable of a business or combinations that seeks to become a new competitive cost producer of drugs made in America. Onboarding production back to the USA creates jobs, mitigates national security risks and will ensure the American people will have clean, pure, cost-efficient medications through a resilient supply chain made in America.
The advisory team includes Charles C. Conaway who is chairman of The Sabre group, a private capital business which has operated, acquired & originated a variety of businesses in the health, consumer and other segments. Mr. Conaway has led and served on the Board of a variety of organizations, including Fortune 100 companies as President of CVS Corporation, where he led the successful restructuring to create CVS as a stand-alone public company. Mr. Conaway was one of the lead architects in transforming CVS from a large retailer to one of largest health care companies in the U.S.
The team also includes Paul J. Mastronardi and Edward A. Robinson.
Mr. Mastronardi is a third-generation greenhouse grower and distributor in the North American market. He was recognized as a Top 10 Under 40 honoree by Greenhouse Canada in 2017 and as a Top 40 Under 40 honoree by Produce Business in 2024. Paul also serves on multiple boards across various industries and brings extensive experience in developing businesses.
Mr. Robinson is the former Chief Executive Officer of BMW Financial Services N.A. He was responsible for the America’s Region, which included BMW Bank, an Industrial Loan Corporation in Salt Lake City, Utah. Since retiring from BMW, Mr. Robinson has acted as a consultant on a wide range of businesses including public and private entities.
The team will leverage resources and networks for efficient outreach to commence immediately. The effort will be focused on creating proprietary transaction opportunities. The Company believe personal relationships built over time are critical not just in generating transaction opportunities, but also in consummating a business combination.
About Drugs Made In America Acquisition Corp.
The Company is a blank check company incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It has not selected any specific business combination target and has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination. While the Company may pursue a business combination target in any business, industry or geographical location, it intends to focus its search for businesses in the pharmaceutical industry. The Company believes that it is possible to mitigate risks in the U.S. medical supply chain by investing in companies that will reduce America’s overreliance on production of pharmaceuticals from concentrated geographic regions through investments in strategic on-shoring of advanced domestic manufacturing technologies for critical drugs.
Contact Information
Drugs Made In America Acquisition Corp.
1 East Broward Boulevard, Suite 700
Fort Lauderdale, FL 33301
Lynn Stockwell
Chief Executive Officer and Executive Chair
Email: lynn@dmaacorp.com
Phone: (954) 870-3099
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. No assurance can be given that the offering discussed above will be completed on the terms described, or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related preliminary prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC's website, www.sec.gov.
FAQ
What is the main objective of DMAAU's newly formed advisory team?
Who are the key members of DMAAU's advisory team announced in February 2025?
What are the strategic benefits of DMAAU's initiative for drug production in America?
How will DMAAU's advisory team approach potential business acquisitions?
